glp 1 drugs news Medicare will now help pay for some GLP-1 drugs. Here's what to know The promises and pitfalls of

In a phase II study of the long-acting GLP-1RA efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 weeks, and 8 mg once every 2 weeks), patients with obesity and without diabetes had statistically significant reductions in body weight compared with placebo after 20 weeks of treatment (differences in least squares means were 6.3 to 7.2 kg

Ribeiro-Silva JC, Tavares CAM, Girardi ACC

Combination Therapies : The integration of GLP-1 agonists with other weight loss agents is under exploration, aiming to create synergies that offer superior weight loss outcomes

Additionally, research into novel delivery technologies, such as microneedle patches and implantable devices, holds the potential to further enhance patient convenience and compliance, thereby expanding the market reach and attractiveness of GLP-1 receptor agonists